ARA-290 Overview
Mechanism of Action
ARA-290 (Cibinetide) is a synthetic 11-amino-acid peptide from the non-erythropoietic portion of EPO. It activates the innate repair receptor (IRR) — a heteromer of EPO receptor and CD131 — without stimulating red blood cell production. IRR activation promotes tissue repair, reduces inflammation, protects neurons, and modulates innate immunity.
~2–3 hours
Timing
Morning
Injection Site
Subcutaneous or intravenous
Food
No restrictions
Common Stacks
- BPC-157 — Tissue repair synergy
- NAD+ — Neuroprotection + energy
ARA-290 Dosing Protocol
Standard Protocol
4–8 weeks2–4 mg SQ daily
Well studied at 4 mg in clinical trials.
Neuroprotection Protocol
28 days4 mg SQ daily
Per clinical trial protocols.
ARA-290 Expected Timeline
Week 1–2
Anti-inflammatory effects; tissue repair initiation
Week 3–4
Neuroprotective benefits
Week 4–8
Sustained repair and neuroprotection
ARA-290 Side Effects
Very well tolerated in clinical trials
Mild headache (uncommon)
Injection site reactions
ARA-290 Research Studies
ARA 290 improves small nerve fiber loss in sarcoidosis
Dahan A, et al. — Mol Med (2013)
Clinical trial: ARA-290 improved small nerve fiber function and reduced neuropathic symptoms via the innate repair receptor.
PubMed: 23508573ARA-290 FAQ
Why doesn't ARA-290 increase red blood cells like EPO?
ARA-290 activates only the innate repair receptor (EPO-R/CD131), not the classical erythropoietic receptor (EPO-R/EPO-R). Provides tissue repair without polycythemia risk.
What conditions is ARA-290 studied for?
Sarcoidosis neuropathy, diabetic neuropathy, chronic kidney disease complications, and wound healing — its tissue-protective properties span multiple conditions.